Vimarsana
Biggest News Aggregation in the World

Page 41 - Program Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Program Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Program Updates Today - Breaking & Trending Today

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - Vimarsana News

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm - $3.6M U.S. Zokinvy® Net Sales in Q1 2021 News provided by Share this article Share this article PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therap...

ProQR Announces First Quarter 2021 Operating and Financial - Vimarsana News

ProQR Announces First Quarter 2021 Operating and Financial

Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022 Positive data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic retinitis pigmentosa, with plans to advance the program into two pivotal Phase 2/3 trials before year end Exclusive worldwide license and discovery collaboration for non-ophthalmic target with Yarrow Biotechnology, an RTW Investments, LP incubated company Strengthened balance sheet with $103.5 million gross proceeds from public offering LEIDEN, Netherlands & CAMBRIDGE, ...

Binance May Add Stock Tokens Coinbase (COIN), after Tesla (TSLA), Also Reports Record-Breaking BNB Token Burn - Vimarsana News

Binance May Add Stock Tokens Coinbase (COIN), after Tesla (TSLA), Also Reports Record-Breaking BNB Token Burn

Binance May Add Stock Tokens Coinbase (COIN), after Tesla (TSLA), Also Reports Record-Breaking BNB Token Burn Leading crypto exchange Binance notes in its weekly report that it completed a record-breaking Binance Coin (BNB) token burn. The weekly report (April 10 – 16, 2021) from Binance reveals that the digital assets firm burned “a record $593 million in BNB.” The digital currency platform also introduced stock tokens. As mentioned in the update from Binance: “Record-breaking BNB burn. For our 15th quarterly BNB Burn (January to March 2021), Binance burned a total of 1,099,888 BNB,...

Mayor De Blasio Proposes Zoning Changes Intended To Promote The City's Recovery - Real Estate and Construction - Vimarsana News

Mayor De Blasio Proposes Zoning Changes Intended To Promote The City's Recovery - Real Estate and Construction

To print this article, all you need is to be registered or login on Mondaq.com. On March 9, 2021, Mayor Bill de Blasio announced a series of proposed citywide zoning text amendments intended to incentivize the creation of local grocery stores, boost transit station accessibility, and ease administrative burdens for gyms and restaurants. The proposed zoning changes are expected to enter the city's public review process this spring or summer, which could put them on track to be approved before the end of this year. FRESH Program Updates The Food Retail Expansion to Suppo...

Source: mondaq.com
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 - Vimarsana News

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020

Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 News provided by Share this article Share this article SAN DIEGO, March 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020. "2020 was a transformative year for Poseida, as we completed ...